ONCOB MDxHealth S.A.

MDxHealth (R): Annual General Shareholders’ Meeting

MDxHealth (R): Annual General Shareholders’ Meeting



NEWS RELEASE                                                                            REGULATED INFORMATION

Annual General Shareholders’ Meeting

IRVINE, CA, and HERSTAL, BELGIUM – [18:00 CEST], May 29, 2019 – MDxHealth SA (Euronext: MDXH) held today its Annual General Shareholders' Meeting in Brussels. The shareholders approved all agenda items of the Annual General Shareholders' Meeting, including the financial statements for the financial year ended December 31, 2018.

In addition, the company held an Extraordinary General Shareholders' Meeting. As the required quorum was not met for this meeting, a new Extraordinary General Shareholders' Meeting will be held on June 21, 2019.

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of therapeutic response. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:



 



Consilium Strategic Communications

David Daley, Chris Welsh, Jonathan Birt, Marieke Vermeersch

UK: 1

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx, PredictMDx and UrNCollect are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.Disclaimer

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.  This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

Attachment

EN
29/05/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MDxHealth S.A.

 PRESS RELEASE

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Can...

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 () – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostic company, announces the introduction of a non-invasive genetic prostate cancer test through its urology sales channel. With a simple saliva sample, the new comprehensive hereditary prostate cancer test offering provides insights into a patient’s risk of developing cancer, d...

 PRESS RELEASE

Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Result...

Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results 2023 revenue grew by 89% to $70.2 million; excluding GPS, revenues up 42%2023 gross margin expanded by 10.7 percentage points over prior yearConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March 6, 2024 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31,...

 PRESS RELEASE

MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Resul...

MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6 MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6 Company to Host Conference Call with Live Q&A, March 6, 2024 at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 21, 2024 – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2023, after market close on Wednesday, March 6, 2...

 PRESS RELEASE

Mdxhealth Announces Resignation of Board Member

Mdxhealth Announces Resignation of Board Member Mdxhealth Announces Resignation of Board Member IRVINE, CA, and HERSTAL, BELGIUM – February 16, 2024 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced that Jan Pensaert has stepped down from the Board of Directors of mdxhealth. His resignation was effective as of February 15, 2024. Mr. Pensaert’s resignation is not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company. Michael K. McGarrity,...

 PRESS RELEASE

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenu...

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue Guidance             MDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM – January 8, 2024 () – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today reported preliminary fourth quarter and full year 2023 revenues and issued 2024 revenue guidance. The Company expects to report fourth quarter and full year 2023 revenues of approximately $19.4 and $70.2 million, respectively, wi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch